Ventura BioMed Investors
Venture capitalMunich · Seed–Series A · 2 people tracked
Investment thesis
Ventura BioMed Investors focuses on early-stage life science companies developing pioneering technologies and innovative therapies. It typically invests EUR 1-5 million per company, always co-investing in consortia with other funds and within Europe. The firm can further expand its reach through Ventura Ace, an investment platform of selected private investors. Led by serial biotech and pharmaceutical entrepreneurs, the firm helps shape the long-term development of its portfolio companies and provides them with access to a broad investor and business network to accelerate medical breakthroughs.
Source: firm website, verified Aug 3, 2026.
Team · 2 people
from the firm's website & public directories
What they invest in
from 5 of 6 portfolio companiesBiotech ×5Deep Tech ×2Healthtech ×2Medical Devices ×2AI & Machine Learning ×1
HQs:Germany×2United States×1
Investments · 6 tracked
founders shown can be your intro path
Kupando is a biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases.
AI & Machine LearningBiotechMedical DevicesSchönefeld, DE
Johanna Holldack(CEO)
BoardPierre Morgon(Chairman)Wolfram Nothaft(Deputy Chairman)
Co-investorsBrandenburg KapitalRemiges Ventures, Inc.
Abalos develops systemically administered therapeutic candidates using its AdaptInnate approach to trigger innate and adaptive immune responses within a patient's tumor.
BiotechHealthtech
Arcoris bio develops MUSE®, a self-assembling, enzyme-free DNA nanotechnology for signal amplification and multiplex imaging that detects protein, DNA, and RNA biomarkers across assays such as immunofluorescence, immunohistochemistry, and in situ hybridization.
BiotechDeep TechMedical Devices
BiotechSkillman, US
Peter Schiemann(Founder)Pawel Zolnierczyk(Executive Officer)
Co-investorsKeiretsu Forum
Immuno-oncology company developing KUP101, a dual TLR 4 and 7 agonist harnessing innate immune stimulation.
TQ Therapeutics develops in vivo cell and gene therapies through its CELLfinity platform and EXiVO approach, aiming to make autologous cell therapy production more scalable and less costly.
BiotechDeep TechHealthtechPlanegg, DE
Portfolio news
latest coverage across their companiesiQure Pharma · geneonline.com · Sep 29, 2025
Frequently asked questions
- How many investments has Ventura BioMed Investors made?
- Ventura BioMed Investors has 5 tracked investments.
- What stage does Ventura BioMed Investors invest at?
- Ventura BioMed Investors invests at the Seed, Series A stages.
- What is Ventura BioMed Investors's typical check size?
- Ventura BioMed Investors typically writes checks of $1.1M – $5.5M.
- What sectors does Ventura BioMed Investors focus on?
- Ventura BioMed Investors focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Ventura BioMed Investors located?
- Ventura BioMed Investors is headquartered in Munich, DE.
- Does Ventura BioMed Investors lead rounds?
- Ventura BioMed Investors typically participates in rounds rather than leading them.
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.